Matt Zuga, CFO & Chief Business Officer at Acumen Pharmaceuticals, Inc. (ABOS), sold 6,888 shares at $1.82 ($13K) on 2026-01-08, disclosed to the SEC on 2026-01-12.
Scheduled sale ($13k) by CFO & Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ABOS | SELL | 2025-01-23 | $57K | — | Filing → |
| ABOS | SELL | 2025-01-07 | $24K | — | Filing → |
| ABOS | SELL | 2024-01-19 | $16K | — | Filing → |